{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:47:00Z","timestamp":1770749220347,"version":"3.50.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40259-025-00745-x","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:42:06Z","timestamp":1759322526000},"page":"923-926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risankizumab in Patients with Psoriasis with Current or Previous Malignancy: A Multicenter, Retrospective Real-World Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Marco","family":"Sousa","sequence":"first","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Jo\u00e3o","sequence":"additional","affiliation":[]},{"given":"Martim","family":"Luz","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[]},{"given":"\u00c2ngela","family":"Roda","sequence":"additional","affiliation":[]},{"given":"Luiz","family":"Leite","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Val\u00e9rio","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Ferreirinha","sequence":"additional","affiliation":[]},{"given":"B\u00e1rbara","family":"Leal","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o Paiva","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Pimenta","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"4","key":"745_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0024.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"745_CR2","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40261-023-01306-2","volume":"43","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Valenti M, Orsini D, Cristaudo A, Frascione P, et al. Safety of interleukin inhibitors in patients with plaque psoriasis and neoplasm: a retrospective study from two referral centers. Clin Drug Investig. 2023;43(10):807\u201312. https:\/\/doi.org\/10.1007\/s40261-023-01306-2. (Epub 2023 Sep 16. PMID: 37715898).","journal-title":"Clin Drug Investig"},{"issue":"9","key":"745_CR3","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/ced\/llaf184","volume":"50","author":"F Satolli","year":"2025","unstructured":"Satolli F, Gerosa S, Burlando M, Cozzani EC, Lasagni C, Manfredini M, et al. Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study. Clin Exp Dermatol. 2025;50(9):1827\u201333. https:\/\/doi.org\/10.1093\/ced\/llaf184. (PMID: 40521671).","journal-title":"Clin Exp Dermatol"},{"key":"745_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/jvc2.600","volume":"4","author":"M Magnano","year":"2025","unstructured":"Magnano M, Rossari S, Trovato E, Capalbo E, Dragotto M, Di Cesare A, et al. Risankizumab in oncologic patients with psoriasis: a case series. JEADV Clinical Practice. 2025;4:558\u201360. https:\/\/doi.org\/10.1002\/jvc2.600.","journal-title":"JEADV Clinical Practice"},{"key":"745_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00951-x","author":"T Torres","year":"2025","unstructured":"Torres T, Jo\u00e3o AL, Luz M, Mendes-Bastos P, Roda \u00c2, Leite L, et al. Real-world effectiveness, safety, and drug survival of risankizumab in adult patients with plaque psoriasis: a 3-year multicenter retrospective cohort study. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00951-x. (Epub ahead of print. PMID: 40413337).","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"745_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466\u201375.","journal-title":"Br J Dermatol"},{"key":"745_CR7","doi-asserted-by":"publisher","unstructured":"Gargiulo L, Ibba L, Valenti M, Costanzo A, Narcisi A. Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma. Melanoma Res. 33(2):152\u20134. https:\/\/doi.org\/10.1097\/CMR.0000000000000875. (PMID: 36728879).","DOI":"10.1097\/CMR.0000000000000875"},{"issue":"1","key":"745_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.23736\/S2784-8671.22.07297-8","volume":"158","author":"G Avallone","year":"2023","unstructured":"Avallone G, Dapavo P, Cabutti F, Preti M, Cavallo F, Roccuzzo G, et al. Regression of human papillomavirus-associated high-grade vaginal intraepithelial neoplasia after switching from ustekinumab to risankizumab in a psoriasis patient. Ital J Dermatol Venerol. 2023;158(1):61\u20132. https:\/\/doi.org\/10.23736\/S2784-8671.22.07297-8. (PMID: 36939503).","journal-title":"Ital J Dermatol Venerol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00745-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:26:26Z","timestamp":1761704786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00745-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["745"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00745-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"17 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval for the version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"Marco Sousa has no conflicts of interest that are directly relevant to the content of this article. Ana Lu\u00edsa Jo\u00e3o has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Janssen, Leo Pharma, Merck, Novartis, and Sanofi. Martim Luz has no conflicts of interest that are directly relevant to the content of this article. Pedro Mendes-Bastos has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Alumis, Amgen, Apogee, Biogen, CS Labs, Eli-Lilly, Evelo Biosciences, Janssen-Cilag, Leo-Pharma, L\u2019Oreal, Novartis, Organon, Pfizer, Pierre Fabre, Regeneron, Sanofi, and Viatris. \u00c2ngela Roda has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Janssen, and Novartis. Luiz Leite, Joana Val\u00e9rio, Ana Ferreirinha, and Barbara Leal have no conflicts of interest that are directly relevant to the content of this article. Maria Jo\u00e3o Paiva Lopes has participated in clinical trials, advisory board, and\/or lectures promoted by AbbVie, Almirall, Boehringer Ingelheim, Janssen, Leo-Pharma, Eli Lilly, Novartis, Pfizer, Sanofi-Genzyme, and Viatris. Rita Pimenta has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Janssen, and LEO Pharma. Paulo Ferreira has received consultancy and\/or speaker\u2019s honoraria from AbbVie, Almirall, Janssen, LEO-Pharma, Lilly, and Novartis. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson and Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patient consent was exempted because of the retrospective nature of the study and the use of de-identified, anonymized, and aggregated data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patient consent was exempted because of the retrospective nature of the study and the use of de-identified, anonymized, and aggregated data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MS and TT contributed to the conception and design of the study. MS, ALJ, ML, PMB, AR, LL, JV, AF, BL, MJPL, RP, PF, and TT\u00a0collected clinical data from the participating hospital centers. MS and TT performed the data analysis and interpretation and drafted the initial version of the manuscript. MS, ALJ, ML, PMB, AR, LL, JV, AF, BL, MJPL, RP, PF, and TT\u00a0critically revised the manuscript for important intellectual content. MS, ALJ, ML, PMB, AR, LL, JV, AF, BL, MJPL, RP, PF, and TT\u00a0read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}